BRK-B vs IREN

The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.

IREN Limited presents a deeply contradictory profile: explosive revenue growth of 355.4% YoY and a 3Y return of +1824.1% signal strong market momentum and potential disruption, yet fundamental red flags abound. The company reports a negative operating margin (-25.02%) and ROA of -0.01%, indicating severe profitability challenges despite a 75.99% profit margin—likely an accounting anomaly or non-operational gain. Valuation metrics are stretched, with a P/E of 26.65 and a Forward P/E of 136.38, far exceeding peers like BLK and SCHW, while insiders have sold $66.26M in shares recently, signaling concern at current levels. Analysts maintain a 'buy' recommendation with a $76.00 target, implying 64% upside, but the lack of earnings beats, negative operating leverage, and deteriorating price action (-31.8% over 1M) suggest significant risk in extrapolating recent performance.